Author:
Pena Polanco Nathalie,Cottone Claudia,Bhamidimarri Kalyan Ram
Publisher
Springer Science and Business Media LLC
Reference105 articles.
1. Vierling JM. Primary sclerosing cholangitis. Schiff’s diseases of the liver 2018.
2. Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590–9.
3. Tabibian JH, Ali AH, Lindor KD. Primary sclerosing cholangitis, part 1: epidemiology, etiopathogenesis, clinical features, and treatment. Gastroenterol Hepatol (N Y). 2018;14(5):293–304.
4. Nayagam JS, Miquel R, Joshi D. Overlap syndrome with autoimmune hepatitis and primary sclerosing cholangitis. EMJ Hepatol. 2019;7(1):95–104.
5. •• Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E, et al. Overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54(2):374–85 This was a position paper that addressed the concept of overlap syndrome and its implications for diagnosis and management. They use of IAIHG scoring system was not recommended to be used in overlap syndrome. Authors recommended that patients with an original diagnosis of AIH who later underwent cholangiography and were proven to have PSCmackmack, should be classified as PSC only, since cholangiographic features of PSC were not excluded at the time of original diagnosis. PSC should be considered in AIH patients with pruritus, cholestatic liver tests, histological bile duct changes, and in those who show a poor response to therapy.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献